SB-030 is under clinical development by Symic Bio and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect SB-030’s likelihood of approval (LoA) and phase transition for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) took place on 11 Nov 2020, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their SB-030 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

SB-030 overview

SB-030 (SBCV-030) is under development for the treatment of critical limb ischemia an advanced stage of peripheral artery disease in end stage renal disease (ESRD) patients undergoing hemodialysis, or in vein graft failure, neointimal hyperplasia, fibrosis and cancers. The drug candidate is ECM-specific compound which mimic the function of natural proteoglycan. The drug candidate is developed based on tissue scaffold technology.

Symic Bio overview

Symic Bio is a biopharmaceutical company. The company develops novel matrix-targeting therapeutics. It’s pipeline products include SB-030 and SB-061. Symic Bio SB-030 is a clinical candidate used for the prevention of peripheral vascular diseases and vein graft failure. The company’s SB-061 is a clinical candidate used for disease modification and pain management in the treatment of osteoarthritis. It also has investigating applications in the areas of oncology, fibrosis and diseases of the central nervous system. The company has partnership with various pharmaceutical companies for the clinical development of osteoarthritis program. Symic Bio is headquartered in Emeryville, California, the US.

Quick View SB-030 LOA Data

Report Segments
  • Innovator
Drug Name
  • SB-030
Administration Pathway
Therapeutic Areas
  • Cardiovascular
  • Musculoskeletal Disorders
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.